Thu, 27 Oct 2016 08:00:00 EDTThe present invention relates generally to a method of diagnosing and/or monitoring the development or progress of chronic fatigue syndrome. More particularly, the present invention relates to a method of diagnosing and/or monitoring the development or progress of chronic fatigue syndrome by analysis of activin βB expression levels in a subject mammal or in a biological sample derived from said mammal. This may be achieved by screening for activin βB in either monomeric form or in dimeric form. Still further, the ratio of the dimeric form of activin βB relative to follistatin and activin A levels also provides a useful diagnostic indicator. In a related aspect there is provided a method for the treatment of chronic fatigue syndrome by downregulating the functional level of activin B.
Thu, 27 Oct 2016 08:00:00 EDTThe present invention relates to bacterial Clp B protein and Clp B expressing bacteria and their impact on eating disorders. The invention further relates to compositions comprising antibiotic directed against at least one Clp B expressing bacterium as well as probiotics not expressing Clp B protein and their use in the treatment or prevention of eating disorders. The invention also relates to diagnostic tools for determining whether a subject is likely to respond to a method of treating eating disorders and to methods of immunization against eating disorders.
Thu, 27 Oct 2016 08:00:00 EDTThe current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the PD-L1 protein that are particularly advantageous for quantifying the PD-L1 protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and/or paraffin embedded. PD-L1 peptides having modified or unmodified residues can be quantitated. An example of a modification of a PD-L1 fragment peptide is a phosphorylated tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence.
Thu, 27 Oct 2016 08:00:00 EDTDescribed herein are compositions and methods of use of anti-Trop-2 antibodies or antigen-binding fragment thereof to isolate, enrich, detect, diagnose and/or characterize circulating tumor cells (CTCs) from patients with a Trop-2 positive cancer. Preferably, the antibody is an RS7, 162-46.2 or MAB650 antibody. The compositions and methods are of use to detect, diagnose and/or treat metastatic Trop-2+ cancers, such as breast, ovarian, cervical, endometrial, lung, prostate, colon, rectum, stomach, esophageal, bladder, renal, pancreatic, thyroid, epithelial or head-and-neck cancer.
Thu, 27 Oct 2016 08:00:00 EDTMethods are disclosed for detecting the likelihood that a subject will develop esophageal adenocarcinoma. Methods are also disclosed for determining if an agent is effective for treatment or prevention of esophageal adenocarcinoma in a subject. Methods are also disclosed for treating a subject. These methods include detecting a level of biglycan, myeloperoxidase, and protein S100-A9 in a biological sample from the subject administered the agent; and comparing the level of biglycan, myeloperoxidase, and protein S100-A9 to a respective control level of biglycan, myeloperoxidase, and protein S100-A9. In some embodiments, these methods also include detecting a level of annexin-A6 in a biological sample from the subject; and comparing the level of annexin-A6 to a respective control level of annexin-A6.
Thu, 27 Oct 2016 08:00:00 EDTThe present invention relates to the field of veterinary diagnostics, specifically to a test for the detection of antibodies against CSFV. In particular the invention relates to a method for detecting antibodies against wild type CSFV in a test sample, characterised in that the method comprises co-incubating with a carrier comprising a mutated TAVSPTTLR epitope of CSFV E2 protein. Further, the invention relates to a diagnostic test kit, and to the use of the method according to the invention. In addition the invention relates to a method for differentiating between animals infected with wild type CSFV and animals that were vaccinated against CSFV with a CSFV (marker) vaccine, and to a method for controlling an infection with wild type CSFV in a population of porcine animals, by the combined use of a CSFV (marker) vaccine and the diagnostic test kit of the invention.
Thu, 27 Oct 2016 08:00:00 EDTHerein is reported an enzyme linked immunosorbent assay for the detection of anti-drug antibodies against a drug antibody in a sample comprising a capture drug antibody and a tracer drug antibody, wherein the capture drug antibody and the tracer drug antibody are employed in a concentration of 0.5 μg/ml or more, the sample is incubated simultaneously with the capture drug antibody and the tracer drug antibody for 1 to 24 hours, the capture drug antibody and the tracer drug antibody are derivatized via a single lysine residue, the sample comprises 10% serum, and oligomeric human IgG is added to the sample prior to the incubation with the capture drug antibody and the tracer drug antibody.
Thu, 27 Oct 2016 08:00:00 EDTProvided herein, in some embodiments, are methods of using certain cereblon-associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), myelodysplasia syndromes (MDS) and acute myeloid leukemia (AML)) and IFN-associated disorders. Also provided herein, in certain embodiments, are methods of determining the efficacy of an immunomodulatory compound.
Thu, 27 Oct 2016 08:00:00 EDTThe invention relates to nanofibers containing photocurable ester derivatives of hyaluronic acid or its salt, the method of preparation thereof, and the photocured preparation made from the nanofibers by light irradiation and the use thereof
Thu, 27 Oct 2016 08:00:00 EDTProvided herein are methods and compositions for the detection of in-frame deletion germline mutations in the CALR gene. Also provided are methods for determining the prognosis of myeloproliferative diseases and the likelihood of developing somatic mutations in genes involved in the JAK-STAT pathway.
Thu, 27 Oct 2016 08:00:00 EDTA method of diagnosing ovarian cancer in a subject is described that includes identifying the expression level of at least one diagnostic miRNA in a biological sample from the subject, comparing the expression level of the at least one diagnostic miRNA to control expression levels, and diagnosing the subject as having or being at an increased risk of having ovarian cancer if the subject has a changed expression level of the one or more diagnostic miRNA. The method also includes a method of providing a prognosis for a subject having ovarian cancer, and kits for carrying out a diagnosis or prognosis of ovarian cancer using miRNA.
Thu, 27 Oct 2016 08:00:00 EDTThe technology described herein relates to assays and methods for the diagnosis, prognosis, and/or treatment of melanoma, e.g. relating to measuring the level of neurophilin-2 (NRP-2) mRNA expressed in melanoma cells. In some embodiments, the level of NRP-2 can be normalized to the level of Melan-A (MART) mRNA.
Thu, 27 Oct 2016 08:00:00 EDTThe technology described herein relates to methods of detecting circulating tumor cells (CTCs), e.g. by detecting changes in the expression of certain CTC marker genes. Aberrant expression of CTC marker genes, e.g. changes in expression indicative of CTCs can also be targeted in order to treat cancer.
Thu, 27 Oct 2016 08:00:00 EDTThe present disclosure describes PD-L1 gene signature biomarkers that are useful for identifying cancer patients who are most likely to benefit from treatment with a PD-1 antagonist. The disclosure also provides methods and kits for testing tumor samples for the biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.
Thu, 27 Oct 2016 08:00:00 EDTThe present disclosure describes gene signature biomarkers that are useful for identifying cancer patients who are most likely to benefit from treatment with a PD-1 antagonist. The disclosure also provides methods and kits for testing tumor samples for the biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.
Thu, 27 Oct 2016 08:00:00 EDTThe invention relates to the identification and selection of differentially expressed transcripts (biomarker) in tumour cells. Specific determination of the level of these biomarkers can be used for screening and diagnosis of prostate cancer. Clinical application of assays based on these biomarker help reduce the high number of false positives of current standard screening assays.
Thu, 27 Oct 2016 08:00:00 EDTThe present invention relates to novel fusion genes comprising NRG1 and a further fusion partner, like CD74. The present invention provides for the use of these fusion genes in diagnosis as well as in medical intervention in cancer.
Thu, 27 Oct 2016 08:00:00 EDTThe present invention is related to novel methods for categorizing and treating subjects having Acute Respiratory Distress Syndrome (ARDS).
Thu, 27 Oct 2016 08:00:00 EDTThe present invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of: (i) determining a genotype of the subject at a location corresponding to the location of one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of: rs1894408, kgp7747883, kgp6599438, rs10162089, rs16886004, kgp8110667, kgp8817856, kgp24415534, kgp6214351 and rs759458, (ii) identifying the subject as a predicted responder to glatiramer acetate if the genotype of the subject contains one or more A alleles at the location of kgp8110667, rs10162089, rs759458 and kgp6214351, or one or more G alleles at the location of kgp24415534, kgp6599438, kgp7747883, kgp8817856, rs16886004 and rs1894408; and (iii) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identified as a predicted responder to glatiramer acetate.
Thu, 27 Oct 2016 08:00:00 EDTThis invention generally relates to lncRNAs and methods for diagnosing cardiac pathologies in a subject. The invention also provides methods for treating a cardiac pathology in a subject comprising administering to said subject an effective amount of a modulator of one or more lncRNAs of the invention.
Thu, 27 Oct 2016 08:00:00 EDTThe present invention relates to a method of genotyping highly polymorphic nucleic acid. In particular, the present disclosure relates to methods for genotyping highly polymorphic gene alleles, such as HLA alleles using high-throughput sequencing technology. More particularly, the present invention relates to a capture probe method that is suitable for identifying alleles in highly polymorphic gene by targeting capture probes to non-coding sequences.
Thu, 27 Oct 2016 08:00:00 EDTA method of identifying a subject having a urinary tract infection posing a significant risk of dangerous sequalae is described. The method includes obtaining a urine or fecal sample from the subject; determining the predominant LPS O-antigen serotype in the sample; and comparing the predominant LPS O-antigen serotype to a set of febrile UTI LPS serotypes. The method can also include treating the subject for UTI if the predominant O-antigen LPS serotype is a febrile UTI LPS serotype.
Thu, 27 Oct 2016 08:00:00 EDTDescribed herein is a method of preventing or treating a disease in a mammalian subject, comprising administering to the subject who is in need thereof an effective dosage of a pharmaceutical composition comprising a virus like particle (VLP) comprising: an alphavirus replicon comprising a recombinant polynucleotide, wherein the polynucleotide comprises a sequence encoding both subunits of a human class II major histocompatibility antigen, a retroviral gag protein, and a fusogenic envelope protein, wherein the VLP does not contain an alphavirus structural protein gene.
Thu, 27 Oct 2016 08:00:00 EDTThe invention relates a method for producing a stable recombinant protein, comprising growing a non-naturally occurring host cell in a culture medium to produce a recombinant protein, and making a composition comprising the recombinant protein and a polysorbate. The production of endogenous lipoprotein lipase by the host cell is reduced. The endogenous lipoprotein lipase is present in the composition in a small amount, and is capable of degrading the polysorbate. The invention also relates to the relevant host cells and compositions, and preparation thereof.
Thu, 27 Oct 2016 08:00:00 EDTThe invention provides immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
Thu, 27 Oct 2016 08:00:00 EDTThe present invention relates to polyC:poly(G/1) dsRNAs for triggering innate immunity, in particular through toll-like receptor 3 (TLR-3) and, optionally, RIG-I or RIG-I—like receptors (RLRs), as well as compositions and medicaments containing such dsRNAs, methods for their production and their use in medicine, especially immunostimulation and prevention and/or therapy of infections and tumor diseases.
Thu, 27 Oct 2016 08:00:00 EDTThe compositions and methods of the disclosure particularly target the divalent metal transporter expressed on olfactory nerve terminals to transport divalent cation-coated or cation-containing nanoparticles to all regions of brain. It has been found that such divalent cation-containing nanoparticles, including those nanoparticles comprising manganese have affinity for the metal transport receptor proteins. Although this receptor has particular affinity for manganese, it is contemplated that other divalent ions, including magnesium, calcium, and the like may also be bound to such receptors leading to transport of the nanoparticles into the intracellular cytoplasm. Nanoparticles have been developed, therefore, as vehicles for parenteral delivery of genes, proteins and drugs. The present disclosure encompasses embodiments of nanoparticle-based compositions and methods for the use thereof for the delivery of genes, oligonucleotides, including but not limited to small interfering RNA, and other small molecule drugs, into the brain by nasal insufflation.
Thu, 27 Oct 2016 08:00:00 EDTNanoparticle compositions and pharmaceutical compositions for the delivery of a polynucleotide and a hydrophobic pharmaceutical agent to a cell or tissue that overexpresses a protease are provided. Methods of making such compositions and methods of using such composition to treat a condition associated with a cell or tissue that overexpresses a protease are provided as well. Also provided are kits for use in treating a condition associated with a cell or tissue that overexpresses a protease. The compositions, methods, and kits can be used to selectively deliver anti-tumor agents to cancer cells.
Thu, 27 Oct 2016 08:00:00 EDTCompositions and methods for treating cancer associated with aberrant activation of the Wnt signaling pathway are disclosed. In particular, the invention relates to R-spondin antagonists comprising a soluble extracellular domain of ring finger 43 (RNF43) or E3 ubiquitin ligase zinc and ring finger 3 (ZNRF3) and methods of treating cancer with such antagonists.
Thu, 27 Oct 2016 08:00:00 EDTDisclosed are novel phosphorylation sites identified in LRRK2 and associated with Parkinson's Disease, antibodies that specifically bind to the novel phosphorylation sites, and laboratory and clinical uses thereof.
Thu, 27 Oct 2016 08:00:00 EDTThe present invention provides compositions and methods of preparing airway cells. In one aspect, an epithelial airway cell derived from an induced pluripotent stem (iPS) cell characterized by expression of airway cell surface markers and an ability to proliferate is described. In another aspect, methods of differentiating an iPS into an epithelial airway cell is provided. Engineered lungs, methods of making such engineered lungs comprising the epithelial airway cells and treating respiratory disorders are also disclosed.
Thu, 27 Oct 2016 08:00:00 EDTThe invention relates to a method of preparing pancreatic islet-like cell structures characterized by a unique combination of morphological and functional features which make them particularly suitable for use in both clinical and drug screening application, as well as to the pancreatic islet-like cell structures obtained therefrom.
Thu, 27 Oct 2016 08:00:00 EDTThe present invention relates to a method for producing dendritic cells with increased capability to activate T cells, to dendritic cells obtainable by such a method, and to a pharmaceutical composition comprising such dendritic cells.
Thu, 27 Oct 2016 08:00:00 EDTA method of preparing Cordyceps cicadae mycelium active substances for preventing and/or treating xerophthalmia is provided. The method comprises: (a)culturing a Cordyceps cicadae mycelium in a plate media at 15 to 35° C. for 5 to 14 days; (b)inoculating the mycelium of step(a) to a flask containing liquid media and culturing it at 15 to 35° C. with a pH of 2 to 8 for 3 days; (c)inoculating the mycelium of step(b) to a fermenter tank and culturing it at 15 to 35° C. with a pH of 2 to 8 for 3 days, so as to obtain a Cordyceps cicadae mycelium fermentation liquid; (d)freeze-drying and grating the fermentation liquid, so as to obtain a Cordyceps cicadae mycelium powder; (e)extracting the powder with solvent, so as to obtain a Cordyceps cicadae mycelium extract; and (f)drying the extract, so as to obtained the Cordyceps cicadae mycelium active substances.
Thu, 27 Oct 2016 08:00:00 EDTProvided is a perfuming method including applying a water-based product to a fabric or a human body and drying, the water-based product containing a perfume precursor composed of an ester of at least one perfume selected from maltol, ethyl maltol, vanillin, ethyl vanillin, and raspberry ketone and at least one aliphatic monocarboxylic acid or aliphatic dicarboxylic acid selected from lauric acid, myristic acid, palimitic acid, stearic acid, oleic acid, adipic acid, and sebacic acid; and subsequently bringing the perfume precursor into contact with moisture in the air to perform hydrolysis, thereby releasing a perfume.
Thu, 27 Oct 2016 08:00:00 EDTThe present invention relates to a ceramic or polycrystalline scintillator composition represented by the formula (LUy-Gd3-y)(GxAI5-x)O12: Ce; wherein y=1±0.5; wherein x=3±0.25; and wherein Ce is in the range 0.01 mol % to 0.7 mol %. The scintillator composition finds application in the sensitive detection of ionizing radiation and may for example be used in the detection of gamma photons in the field of PET imaging.
Thu, 27 Oct 2016 08:00:00 EDTCurable antifouling compositions include fluorinated polymers that contain a perfluoropolyether group, a poly(alkyleneoxide) group, a hydrolyzable silane group and a cationic curative. The curable antifouling compositions can be applied on a surface of a substrate, and at least partially cured to provide an article with antifouling properties.
Thu, 27 Oct 2016 08:00:00 EDTProvided herein are improved fluorogenic compounds and probes that can be used as reagents for measuring, detecting and/or screening hypochlorous acid or hydroxyl radical. The fluorogenic compounds of the invention can produce fluorescence colors, such as green, yellow, red, or far-red. Also provided herein are fluorogenic compounds for selectively staining hypochlorous acid or hydroxyl radical in the mitochondria of living cells. Provided also herein are methods that can be used to measure, directly or indirectly, the presence and/or amount of hypochlorous acid or hydroxyl radical in chemical samples and biological samples such as cells and tissues in living organisms. Also provided are high-throughput screening methods for detecting or screening hypochlorous acid or hydroxyl radical or compounds that can increase or decrease the level of hypochlorous acid or hydroxyl radical in chemical and biological samples.
Thu, 27 Oct 2016 08:00:00 EDTIn an example, a process for bonding a microcapsule having an encapsulating payload to a polymeric material. The process includes applying a microcapsule (having the encapsulated payload) that includes a dienophile functional group to a polymeric material that includes a diene functional group. The process further includes bonding the microcapsule having the encapsulated payload to the polymeric material via a chemical reaction of the dienophile functional group with the diene functional group.
Thu, 27 Oct 2016 08:00:00 EDTThe present invention concerns compositions and methods of use of bispecific antibodies comprising at least one anti-TNF-α antibody or antigen-binding fragment thereof and at least one anti-IL-6 antibody or antigen-binding fragment thereof. Preferably, the bispecific antibody is in the form of a DNL® complex. The anti-TNF-α or anti-IL-6 antibodies may comprise specific CDR sequences disclosed herein. The compositions and methods are of use to treat autoimmune disease, immune system dysfunction or inflammatory disease, as disclosed herein.
Thu, 27 Oct 2016 08:00:00 EDTThe present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.
Thu, 27 Oct 2016 08:00:00 EDTCertain embodiments are directed to composition and methods related to DCLK1-S specific binding agents.
Thu, 27 Oct 2016 08:00:00 EDTMethods for diagnosing or treating immune disorders in a subject are provided. The methods are based on the detection or modulation of Refractory state Inducing Factor (RIF).
Thu, 27 Oct 2016 08:00:00 EDTDisclosed herein are monoclonal antibodies or binding portion thereof that bind specifically to a Staphylococcus spp. autolysin N-acetylmuramoyl-L-alanine amidase catalytic domain and/or cell wall binding domain, as well as pharmaceutical compositions containing the same. Cell lines expressing the monoclonal antibodies, including hybridomas, are also disclosed. Methods of using the monoclonal antibodies for installation of orthopedic implants, grafts or medical devices, treating or preventing a Staphylococcus infection, and treating osteomyelitis are described, as are diagnostic methods for the detection of Staphylococcus in a sample.
Thu, 27 Oct 2016 08:00:00 EDTProvided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-associated disorder or disease and methods of diagnosing a KIT-associated disorder or disease using the antibodies described herein.
Thu, 27 Oct 2016 08:00:00 EDTThere is disclosed compositions and methods relating to or derived from anti-ErbB3 antibodies. More specifically, there is disclosed fully human antibodies that bind ErbB3, ErbB3-binding fragments and derivatives of such antibodies, and ErbB3-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having ErbB3 related disorders or conditions, including various inflammatory disorders and various cancers.
Thu, 27 Oct 2016 08:00:00 EDTProvided herein are methods of identifying a subpopulation of ovarian cancer patients who would be responsive to treatment regimens that target folate receptor alpha (FRA)-expressing ovarian tumors and methods of treatment of such patients using an anti-FRA therapeutic agent, such as an antigen-binding protein (e.g., antibody or antigen-binding fragment thereof) that specifically binds to FRA. Also provided are related kits for identification and treatment of the subpopulation of ovarian cancer patients.
Thu, 27 Oct 2016 08:00:00 EDTDisclosed is a monoclonal antibody binding to an ITM2A protein. This antibody is useful in the diagnosis, prevention, and treatment of cancer such as Ewing's sarcoma, T cell leukemia, T cell lymphoma, acute myeloid leukemia, B cell tumor, and multiple myeloma. The present invention also provides a pharmaceutical composition, a cell growth inhibitor, and an anticancer agent containing the antibody as an active ingredient, and a method for treating cancer, a method for predicting the efficacy of cancer treatment, and a method for determining the presence of cancer in a test subject using the antibody.
Thu, 27 Oct 2016 08:00:00 EDTThe present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides bi-specific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.
Thu, 27 Oct 2016 08:00:00 EDTThe present invention includes unique, isolated monoclonal antibodies that bind human RON, and methods for making and using the same.